Compare Neurocrine Biosciences Inc (NBIX) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs IAC/Interactivecorp — how do they compare? Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B), while IAC/Interactivecorp trades at $40.21 (market cap $3.03B). The key difference: Neurocrine Biosciences Inc is far larger — about 5.5× IAC/Interactivecorp's market cap. Which is the better fit depends on your goals.
| NBIX | PPLI | |
|---|---|---|
Market Cap | $16.76B | $3.03B |
Sector | Health | Media |
52-Week High | $185.50 | $47.62 |
52-Week Low | $123.10 | $31.52 |
Enterprise Value | $16.78B | $3.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
People Incorporated (PPLI) trades at $41.58, down 3.17% amid bearish technical signals despite strong Q2 2026 earnings beat. The company shows mixed fundamentals with attractive valuation ratios (P/E 7.04, P/B 0.61) but volatile profitability trends. Recent news highlights digital revenue growth, corporate restructuring, and MGM investment gains, while institutional activity shows mixed positioning with Amundi increasing stake by 397.4% in Q2 2026.
PPLI presents a value opportunity with deep discount to analyst consensus target of $60.50 (45% upside), though investors face execution risks from restructuring and inconsistent earnings history. The stock's near-term direction hinges on successful asset monetization and sustained digital growth against backdrop of negative cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
